Canale et al. engineered the bacterial strain Escherichia coli Nissle 1917 to recycle ammonia into arginine, and showed synergistic responses with anti-programmed cell death 1 ligand 1 therapy in tumour-bearing mice when injected intratumourally or given systemically.